The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hinchliffe, S. J.
Right arrow Articles by Morgan, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hinchliffe, S. J.
Right arrow Articles by Morgan, B. P.
The Journal of Immunology, 1998, 161: 5695-5703.
Copyright © 1998 by The American Association of Immunologists

Molecular Cloning and Functional Characterization of the Rat Analogue of Human Decay-Accelerating Factor (CD55)1 ,2

Stewart J. Hinchliffe, O. Brad Spiller, Neil K. Rushmere and B. Paul Morgan3

Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff, United Kingdom


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We report here the cloning of cDNAs encoding two forms of the rat analogue of human decay-accelerating factor (DAF; CD55). Screening of a rat kidney cDNA library using a mouse DAF probe identified a partial cDNA encoding the 3' end of rat DAF. The 5' end of the cDNA was cloned using the rapid amplification of cDNA ends (RACE) technique. A second form of rat DAF was identified using 3'RACE. Cloning and sequencing of full length cDNAs for both forms showed that they were identical up to nucleotide 1143 except for a 51-bp insert in the ST-rich region of the second form. After nucleotide 1143, the two sequences diverged; the cDNA cloned from the library encoded a unique 112-amino acid "tail," whereas the second form, identified by 3'RACE, encoded an 18-amino acid hydrophobic stretch, which was predicted to be a glycosylphosphatidylinositol (GPI) anchor addition signal. Expression in the NIH-3T3 mouse fibroblast cell line confirmed that the short tail did encode a GPI-addition signal, whereas the longer tail caused the protein to be secreted. Northern blot analysis identified two distinct transcripts for the GPI form, as well as a variability in expression levels of the different transcripts in the panel of tissues screened. Southern blot analysis showed that both the GPI and secreted forms of rat DAF were expressed in a wide range of tissues. The GPI-linked form of rat DAF stably expressed in a murine fibroblast cell line reduced C3 deposition and conferred protection from lysis by rat serum.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Protection of self cells against autologous complement (C) is mediated by a family of membrane-bound C regulatory proteins (CRP)4 present on host cells (1). In man, three CRP act to inhibit the C3 convertases of the activation pathways: decay-accelerating factor (DAF: CD55), membrane cofactor protein (MCP; CD46), and C receptor 1 (CR1; CD35). These are structurally related molecules, all encoded in the regulators of C activation (RCA) gene cluster on chromosome 1q32 and characterized by the presence of several tandem repeats of a 60-amino acid structural motif termed the short consensus repeat (SCR) (2, 3). DAF is a 70-kDa member of the RCA family, which in man is widely and abundantly expressed on hemopoietic cells, endothelium, and epithelium as well as in diverse tissues (reviewed in 4 .

DAF is a glycosylphosphatidylinositol (GPI)-linked glycoprotein comprising four SCR domains followed by a serine/threonine rich-stretch that is heavily O glycosylated (5). The C regulatory activity of DAF resides in its ability to accelerate the decay of the classical and alternative pathway C3 convertases, C4b2a and C3bBb. Several mAbs capable of inhibiting the function of DAF have been generated, and all of these target SCR3, indicating that this region is critical for association with the C3 convertase (6). However, deletions of individual SCRs demonstrate that SCR2 and -3 are both required for efficient regulation in the classical pathway, while SCR2, -3, and -4 are all required for alternative pathway regulation (7). A second form of human DAF is generated by alternative splicing in the gene, causing a frame shift resulting in a hydrophilic carboxyl terminus, which is predicted to encode a secreted form of the protein (8).

DAF was isolated from guinea pig erythrocytes a year before the isolation of human DAF (9). Subsequently, progress on characterizing decay-accelerating activities from nonhuman species has been slow. A rabbit analogue of DAF was isolated in 1987 (10), mouse DAF was identified in 1989 (11), and DAF was purified from orangutan erythrocytes in 1990 (12). Although DAF in each of these species was similar in many respects to the human protein, some interesting differences emerged. Guinea pig, rabbit, and orangutan DAF were all GPI anchored, but mouse DAF was suggested to contain both GPI-anchored and transmembrane forms. Guinea pig erythrocyte DAF was shown to consist of three distinct species with a molecular mass of 55, 70, and 88 kDa, respectively, all of which had identical amino-terminal sequences (13). In the rat, the only regulator of the C3 convertases so far described is Crry, a 6- or 7-SCR transmembrane molecule that has both decay accelerating and cofactor activities for the convertases and has been suggested to fulfill the roles of both MCP and DAF (14, 15). In order to better understand the factors controlling C activation in rodents during the induction of experimental models of C-mediated disease, it is essential to comprehend fully the regulatory proteins involved. Therefore, we have set out to identify and characterize CRP in the rat. We report here the identification and functional and molecular characterization of the rat analogue of DAF.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Materials

Molecular biology. All general reagents were from Sigma Chemical (Poole, U.K.) unless otherwise stated. Rat cDNA and genomic libraries were from Stratagene (La Jolla, CA). UltraSpec RNA isolation medium was from Biotecx, (Houston, TX). RNase H- Superscript reverse transcriptase, RNase H, terminal deoxynucleotide transferase, and all restriction enzymes were from Life Technologies (Paisley, U.K.). Nick columns for radioactive probe purification, Taq polymerase, and buffers were from Pharmacia (Milton Keynes, U.K.), Vent DNA polymerase was from New England Biolabs (Hitchin, U.K.), and dNTPs were from Bioline (London, U.K.). The RNase inhibitor rRNasin and the pGEM-T vector kit were from Promega (Southampton, U.K.). Geneclean II DNA purification kit was from Anachem (Luton, U.K.), and plasmid purification kits were from Qiagen (Dorking, U.K.). Hybond-N nylon membranes, Rapid-Hyb buffer, Rediprime DNA labeling system, and [{alpha}-32P]dCTP were from Amersham (Little Chalfont, U.K.). Oligonucleotide primers were synthesized in-house on an ABI model 394 synthesizer (Applied Biosystems, Warrington, U.K.). The expression vector pDR2EF1{alpha} was a gift from Dr I. Anegon (Institut National de la Santé et de la Recherche Médicale U437, Nantes, France) (16) and contains the hygromycin resistance gene, which allows the selection of stable colonies, and the powerful polypeptide chain elongation factor 1{alpha} promotor.

Tissues, cells, and sera. Mouse and rat sera were obtained fresh from the animal facility of the University of Wales College of Medicine. All serum was stored at -70°C. Rat erythrocytes were obtained fresh from the same facility and collected into 20 mM EDTA before processing for Western blot and flow cytometry. The mouse fibroblast cell line NIH-3T3 was obtained from the European Collection of Animal Cell Cultures (Porton Down, U.K.). The rat fibroblast cell line RAT2 was obtained from the American Type Culture Collection (Manassas, VA). All cell lines were propagated in DMEM supplemented with 10% FCS, glutamine, pyruvate, and penicillin/streptomycin.

Antibodies. mAbs against rat DAF (RDIII-7 and RDII-24) were generated by repeated immunization of BALB/C mice with NIH-3T3 cells transfected with rat DAF cDNA as described below. The transfected cells were used as immunogen and for screening clones for anti-DAF reactivity. The production and characterization of anti-rat DAF mAbs will be described in detail elsewhere. Mouse monoclonal anti-human C3 (C3/30; known to cross-react with rat C3) was the kind gift of Dr. Peter Taylor (Novartis, Horsham, U.K.). Horseradish peroxidase-conjugated secondary Abs against mouse and rabbit Ig were obtained from Bio-Rad Laboratories (Hertfordshire, U.K.). Phycoerythrin-conjugated secondary Abs against mouse and rabbit Ig were obtained from Dako (Buckinghamshire, U.K.) and Sigma-Aldrich (Dorset, U.K.), respectively. Mouse monoclonal anti-rat CD59 (6D1) was raised in this laboratory and is described elsewhere (17). Mouse monoclonal anti-human DAF (1H4) was a kind gift from Dr. Wendell Rosse (Duke University, Durham, NC).

Screening a rat cDNA library

A 489-bp probe encompassing nucleotides 4–492 of the mouse DAF cDNA sequence (GenBank accession no. L41366) was generated by PCR from mouse testis cDNA and isolated by elution from a low melting point agarose gel. The probe was radiolabeled with [{alpha}-32P]dCTP using the Rediprime kit (Amersham) according to the manufacturer’s protocol. The labeled probe was purified from residual nucleotide using a Nick column (Pharmacia). A rat kidney Uni-ZAP XR cDNA library (Stratagene) was plated out at 40,000 plaque-forming units (pfu) per plate and grown on a lawn of XL1-Blue Escherichia coli for 8 h. Duplicate lifts were taken using Hybond-N nylon membranes. These were denatured in 1.5 M NaCl/0.5 M NaOH, neutralized in 1.5 M NaCl/0.5 M Tris (pH 8.0), washed in 2x SSC, and UV cross-linked in a Stratagene Stratalinker. Membranes were prehybridized in Rapid-Hyb buffer for 1 h at 55°C before addition of the radiolabeled probe and incubation for a further 18 h at 55°C. Membranes were then washed (twice in 1x SSC/0.1% SDS for 10 min at room temperature and once in 0.2x SSC/0.1% SDS for 5 min at 65°C) and exposed to x-ray film for 18 h at -70°C.

Agar plugs containing plaques positive on both of the duplicate membranes were picked, eluted in 1 ml saline magnesium buffer for 24 h, and replated. The above screening protocol was then repeated. Individual positive plaques were picked and eluted in saline magnesium buffer. The cDNA insert was recovered from the phage using the Exassist/SOLR system (Stratagene). Individual bacterial colonies containing recombinant phagemid were grown in Luria-Bertani broth containing 50 µg/ml kanamycin, and the phagemid DNA was purified using a QIAprep spin plasmid miniprep kit (Qiagen). Automated sequencing was conducted in-house using an ABI model 377 DNA sequencer (Applied Biosystems).

Derivation of the 5' end of rat DAF cDNA

The 5' end of the cDNA encoding rat DAF was obtained using a modification of the rapid amplification of cDNA ends (RACE) method described by Frohman (18). A rat DAF-specific primer RDAF-RT (ATTTCCAACCAGAATGAAGCC) (6 pmol), derived from the cDNA sequence obtained from the cDNA library clone, was used in the reverse transcription of the 5' end of the mRNA from 10 µg total RNA from rat kidney. After reverse transcription, the RNA was degraded by incubation for 20 min at 37°C with 2.5U RNase H. The single-stranded cDNA generated by reverse transcription was purified from primers and enzyme using the Geneclean II kit (Anachem). The purified cDNA was polyadenylated at its 3' end by incubation with 10 U of terminal deoxynucleotide transferase (Life Technologies) in the presence of 5 mM ATP at 37°C for 5 min, then 65°C for 10 min. The mixture was heated to 95°C to denature the enzyme, and 5% of the resulting polyadenylated single-stranded cDNA was used directly in the first PCR amplification. Second-strand synthesis was performed using a poly(dT) adaptor primer QT (CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCT17), which binds to the newly synthesized poly(A) tail and consequently adds an extra 35 bases of unique sequence to the cDNA end. PCR amplification of the rat DAF cDNA was performed using primers specific for this unique sequence, Q0 (CCAGTGAGCAGAGTGACG) and Q1 (GAGGACTCGAGCTCAAGC), and the rat DAF-specific primers RDAF-E (CTTTCCTCTCGAATTCTTCC), RDAF-D (GATTTTTGGTGGGTCTGGAC), and RDAF-L (CAGTTCTCTAGGATTAGGGC), which were designed from the cDNA sequence obtained from the degenerate PCR reaction. In the first amplification, the cDNA was amplified using 3 pmol QT primer, 25 pmol Q0, and 25 pmol RDAF-E, under the following conditions: 96°C for 5 min, 50°C for 2 min (ramp, 2.5), 72°C for 40 min, followed by 30 cycles of 94°C for 1 min, 58°C for 1 min, and 72°C for 2 min. A 1-µl aliquot of a 1:20 dilution of the first reaction was reamplified using 25 pmol of each of the nested primers Q1 and RDAF-D under the following conditions: 94°C for 1 min, 60°C for 1 min (ramp, 2.5), and 72°C for 2 min for 30 cycles. A 1-µl aliquot of a 1:20 dilution of the second reaction was further amplified by the nested primers Q1 and RDAF-L under the same conditions.

Derivation of the 3' end of rat DAF GPI cDNA

The 3' end of the cDNA encoding the GPI-anchored form of rat DAF was obtained using a modification of the RACE method, described by Frohman (18). The poly(dT) adaptor primer QT (28 pmol) was used to reverse transcribe mRNA from 10 µg of total RNA from rat testes, kidney, and lung. Nested PCR was performed using Q0 and Q1 along with rat DAF-specific primers RDAF-A (GAGGAATTAGTATGGTCTCC), RDAF-B (CCAACTGACATATTATTCGG), and RDAF-C (CAAAGGGTACAAGCTGGTCGG), designed from the cDNA sequence obtained from the clones isolated from the cDNA library. In the first amplification, 7% of the QT-primed cDNA was amplified using 25 pmol of primers Q0 and RDAF-A under the following reaction conditions: 94°C for 30 s, 56°C for 1 min (ramp, 2.5), and 72°C for 2 min for 30 cycles. In the second amplification, a 1-µl aliquot of a 1:20 dilution of the first reaction was amplified using 25 pmol of Q1 and 25 pmol of RDAF-B under the following reaction conditions: 94°C for 30 s, 60°C for 1 min (ramp, 2.5), and 72°C for 2 min for 30 cycles. In the third amplification, a 1-µl aliquot of a 1:20 dilution of the second amplification was amplified using 25 pmol of Q1 and 25 pmol of RDAF-C under the following reaction conditions: 94°C for 30 s, 60°C for 1 min (ramp, 2.5), and 72°C for 2 min for 30 cycles.

Cloning and sequencing of PCR products

Purified PCR products were ligated into the pGEM-T vector (Promega) according to manufacturer’s protocol. The vector was then electroporated into electrocompetent DH5{alpha} E. coli at 2.5 kV, 25 µFD, and 200 {Omega} using a Bio-Rad Genepulser, and transformed bacteria were selected out by ampicillin resistance. Positive colonies were picked and grown overnight in LB broth containing 50 µg/ml ampicillin at 37°C, and the plasmids were purified using the QIAprep spin plasmid kit (Qiagen).

Automated sequencing was conducted in-house using an ABI model 377 DNA sequencer (Applied Biosystems).

Northern blot analysis

Total RNA was extracted from tissue samples using UltraSpec RNA isolation reagents (Biotecx). Messenger RNA was isolated from 0.5–1 mg of total RNA using the Poly(A)ttract magnetic isolation kit (Promega). Purified mRNA (2–3 µg) was separated on a 1% formaldehyde-agarose gel, transferred to Hybond-N nylon membranes (Amersham), and probed using 32P-labeled cDNA probes specific for glyceraldehyde phosphate dehydrogenase (GAPDH; gift of Dr. D. Llewellyn, Department of Medical Biochemistry, University of Wales College of Medicine) or SCR1–4 of rat DAF. RNA markers (Promega) were used to determine the size of the RNA species identified by autoradiography.

RT-PCR analysis

Total RNA from rat tissues was reverse transcribed using random hexamer DNA primers. The presence of cDNA encoding the two forms of rat DAF was determined by PCR using primer MRDAF-T (GGAGACTGCGGCCCACCTCC) along with either RD59-Y (GGTGGATCCGACCATTCCAGACAACCTCC) or RD59-Z (GGTGGATCCTTTCCCACTTAACAATGCCC) to amplify the full length coding sequences, excluding the signal peptide. Cycling conditions were: 94°C for 30 s, 56°C for 30 s, 72°C for 2 min for 5 cycles, followed by 94°C for 30 s, 66°C for 30 s, and 72°C for 2 min for 25 cycles. The PCR products were run on a gel, blotted, and probed using specific probes. Primers specific for GAPDH were used to amplify the cDNA as an internal control.

Southern blot analysis

Genomic DNA was prepared from rat tail snips (1 mm) as described elsewhere (19). The DNA (10 µg) was digested with four restriction enzymes that did not cleave within the rat DAF cDNA sequence, BamHI, EcoRV, PstI, and XbaI, in single and double digests. The digested DNA was run on a 0.8% agarose gel, denatured with 0.5 M NaOH, neutralized with 1 M Tris (pH 7.5), and blotted onto Hybond-N membranes. After UV cross-linking, the membranes were probed with radiolabeled DNA probes specific for SCR1 and -3 of rat DAF, generated as described above.

Screening a rat genomic library

The templates corresponding to the four SCRs were generated individually by PCR and radiolabeled with [{alpha}-32P]dCTP as described above. A rat kidney {lambda} FIX II genomic library (Stratagene) was plated at 40,000 pfu/plate and grown on a lawn of XL1-Blue MRA (P2) strain E. coli for 8 h. Lifts were taken and hybridized as above. Agar plugs containing plaques positive on both of the duplicate membranes were picked, eluted in 1 ml SM buffer for 24 h, and replated. The above screening protocol was then repeated. Individual positive plaques were picked and eluted in SM buffer.

Purification of genomic phage DNA

Phage was plated at sufficient density to give complete host bacterial lysis of the lawn of XL1-Blue after an overnight incubation. The phage from these fully lysed plates was eluted in 10 ml of SM buffer for 5 h. The buffer, containing eluted phage, was transferred to a 50-ml Falcon tube, 1 ml chloroform was added, and the tube was vortexed and centrifuged at 8000 x g for 10 min to pellet any bacterial or agarose debris. The supernatant was transferred to a fresh tube; 5 U RNase A, 18,000 U RNase T1, and 600 U DNase 1 were added; and the mixture was incubated at 37°C for 30 min.

The {lambda} phage particles were precipitated by the addition of 6 ml of solution 1 (20% polyethylene glycol (PEG 8000), 2 M NaCl, in SM buffer) on ice for 45 min. The mixture was centrifuged at 8000 x g for 20 min and the pellet air dried before resuspension in 0.5 ml SM buffer. Solution 2 (200 µl; 1.5% SDS, 0.3 M Tris-HCl, pH 8.0, 0.15 M EDTA) was added and the mixture incubated at 68°C for 15 min to lyse phage particles. Addition of 250 µl of solution 3 (3 M potassium acetate, 11.5% v/v glacial acetic acid) followed by incubation on ice for 20 min before centrifugation at 1300 rpm for 10 min. The supernatant was transferred to a separate tube and the DNA precipitated by addition of 0.5 volumes of isopropanol and incubation on ice for 5 min, followed by centrifugation. The pellet was resuspended in TE buffer and the DNA reprecipitated by the addition of 2.5 µl 5 M NaCl and 100 µl ethanol. After a 75% ethanol wash, the pellet was resuspended in 50 µl Tris-EDTA (TE) buffer.

Digestion of the phage DNA with NotI allowed recovery of the genomic DNA insert, which was ligated into pBluescript, previously cut with NotI and dephosphorylated using shrimp alkaline phosphatase (Boehringer Mannheim, Lewes, U.K.).

Clones containing the genomic inserts were purified and used as a template for PCR within and between exons, using primers from within the individual SCRs. To sequence the remainder of the signal peptide, genomic clones positive for SCR1 were digested with pst1 and BamHI restriction enzymes in single and double digests. These fragments were run on agarose gels, purified by Geneclean (Anachem), and ligated into pBluescript, previously digested with the same enzymes. After electroporation into DH5{alpha} bacteria, clones were PCR screened and sequenced.

Expression of rat DAF

At the time we wished to express rat DAF, the signal peptide sequence was not identified. We therefore generated by two-stage PCR a construct in which the cDNA encoding the signal peptide from mouse DAF was coupled to the rat DAF GPI-coding region cDNA. Two primers, MRDAF-R (GGTTCTAGATTCTACCTGGGGCTATGATCC) and MRDAF-S (GGCATTAGGAATGTCTGGAGG), were designed to PCR amplify the mouse DAF signal peptide, including the Kozak sequence essential for ribosomal recognition of the translational start site, and a 36-bp region of exact homology between mouse and rat DAF. The GPI-specific primer RD59-Y along with MRDAF-T (described above) was used to PCR amplify the cDNA for the putative GPI-anchored form of rat DAF. These two PCR products were then mixed in equimolar ratios and PCR amplified using the two outside primers MRDAF-R and RD59-Y to give the full length construct. Vent DNA polymerase (New England Biolabs) was used in all PCRs to minimize the introduction of errors. The PCR primers MRDAF-R and RD59-Y contained XbaI and BamHI restriction sites, respectively, ensuring the correct orientation of the insert in the pDR2{Delta}EF1{alpha} expression vector. After electroporation into DH5{alpha}, colonies were picked and the plasmids purified. The presence and fidelity of the rat DAF cDNA construct in the vector was confirmed by DNA sequencing. The insert was released by digestion with XbaI and EcoRI, purified from an agarose gel using Geneclean II (Anachem), and ligated into the pDR2{Delta}EF1{alpha} expression vector, which had been digested with XbaI and EcoRV. An identical strategy was used with the cDNA encoding the putative secretory form of DAF.

The NIH-3T3 murine fibroblast cell line was transfected using lipofectamine, as described (20, 21), with the empty expression vector (negative control) or with expression vectors containing either form of rat DAF cDNA, human DAF cDNA, or rat CD59 cDNA. Surface expression of each molecule was assessed by flow cytometry using saturating amounts of the appropriate mAbs or irrelevant control Abs, followed by a phycoerythrin-conjugated secondary Ab. The effects of various agents on the surface expression of rat and human DAF were examined. To remove nonspecific binding, cells were subjected to two cycles of acid washing in PBS at pH 2, followed by three washes in PBS at pH 7. Trypsin sensitivity and susceptibility to cleavage by phosphatidylinositol-specific phospholipase C (PIPLC; 0.4 U/ml, Peninsula Laboratories, St. Helens, U.K.) were assessed by incubation at 37°C for 90 min with the appropriate enzyme. Cells were then stained as described above for flow cytometry. All samples were run in triplicate, and each experiment was replicated on at least four separate occasions.

Expression of rat DAF was confirmed by Western blotting of cell lysates and growth media. Cells were grown to confluency in 80-cm2 cell culture flasks; fresh medium was then added and the cells grown for a further 72 h. Medium was decanted, centrifuged to remove cellular debris, and mixed with an equal volume of reducing or nonreducing SDS-PAGE sample buffer. Cells were harvested by scraping from a confluent 80-cm2 flask and centrifuged at 2,000 x g for 10 min. This pellet was resuspended in 0.5 ml of ice-cold 1% Triton X-114 in hypertonic lysis buffer, pH 7, and vortexed for 30 min. Insoluble material was removed by centrifugation at 13,000 x g at 4°C, and the supernatant was layered onto 0.5 ml of ice-cold 6% sucrose/1% Triton X-114, and incubated at 37°C for 15 min to allow phase separation. The lower detergent-rich layer was recovered after centrifugation and mixed with an equal volume of nonreducing loading buffer. The same protocol was also used with 100 µl of packed rat erythrocytes. Aliquots (10 µl) were run on 10% SDS-PAGE gels. Gels were blotted and probed with Abs as described previously (22).

Functional assays

The GPI-DAF-transfected cells and vector-transfected cells were cultured overnight in 24-well plates (105 cells/well). NIH-3T3 cells spontaneously activate rat, mouse, and human C (our unpublished observations), but to gain maximal C3 deposition, normal rat serum was mixed at a 3:1 ratio with serum taken from rats that had been previously immunized with untransfected NIH-3T3 cells. To measure C3 deposition, adherent cells cultured for 24 h were washed twice in PBS and overlayed with a 1:4 dilution of rat serum in veronal-buffered saline. Following a 10-min incubation at 37°C, the serum was removed and the cells were washed in flow cytometry medium (FCM; PBS/2% BSA/15 nM EDTA), which both stopped activation of C and disaggregated the cells for flow cytometry. The cells were resuspended in FCM to 0.5 ml, and 0.25 ml was removed and incubated with a 1/100 dilution of monoclonal anti-C3 Ab (C3-30), while the remaining 0.25 ml was incubated with the same dilution of isotype-matched control Ab (OX-23). The cells were then analyzed by flow cytometry. Background staining (OX-23) was subtracted from the value for C3 binding for each sample.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Isolation of rat DAF cDNA from a kidney library

Screening of a rat kidney cDNA phage library (4.8 x 105 pfu) with a mouse DAF probe identified two positive clones from separate plates, which were isolated and sequenced in their entirety. Both contained identical sequences of 1411 bp in length within which was a region of 678 bp which was highly homologous to the published mouse DAF cDNA encoding amino acids 106–335 (22). Through this region, which encompassed part of SCR2, all of SCR3 and 4, and the ST-rich region in mouse DAF, the predicted amino acid sequence was 65% identical, strongly indicating that the isolated cDNA was a rat analogue of DAF. The remaining 733-bp region, encoding 112 amino acids before the stop codon, was not homologous with any of the reported forms of mouse, human, or guinea pig DAF at the amino acid or nucleotide level. The amino acid sequence of this 112-amino acid "tail" had no consensus GPI-addition signal and no hydrophobic domains indicative of a transmembrane protein, raising the possibility that it might be a secreted protein (hereafter termed "secreted").

Cloning of rat DAF using RACE

A 5'RACE approach was used to clone the cDNA encoding the amino-terminal portion of rat DAF. After three rounds of PCR amplification, a single 453-bp product from rat kidney cDNA was cloned and sequenced. This cDNA encoded SCR1 and 2 as well as part of the signal peptide of rat DAF. Despite several further attempts and many modifications of the RT reaction, we were unable to isolate longer products containing the rest of the signal peptide and the 5' untranslated region (UTR).

To determine whether other forms of rat DAF cDNA existed with different 3' ends, as shown in other species, 3'RACE was performed on mRNA from rat testes, lung, and kidney. After three rounds of amplification, a single 971-bp product was obtained from all three tissues. Sequencing of the cloned PCR product revealed a 3' sequence different from that in the clone isolated from the cDNA library. The two sequences were identical up to residue 1143 in the coding sequence except that the PCR product contained an additional 51-bp sequence encoding a stretch of 17 amino acids in the ST-rich region (residues Lys293–Val309 in the coding region; underlined in Fig. 1Go). After residue Gly347, the two sequences diverged; instead of encoding the unique 112-amino acid tail, the PCR product encoded an 18-amino acid hydrophobic stretch that was highly predictive of a GPI anchor addition signal (hereafter termed GPI).



View larger version (44K):
[in this window]
[in a new window]
 
FIGURE 1. Nucleotide and deduced amino acid sequence of rat DAF GPI and secretory forms. Both sequences are identical up to and including residue Gly347. The first residue of the mature protein (D-1) is underlined. The nucleotide sequence for the 51-bp sequence in the ST-rich region, present only in the GPI form, is underlined. Potential N-glycosylation sites (N-X-S/T) are denoted by {psi}. The arrow ({Downarrow}) indicates the predicted GPI-anchor addition site (N-338). The GenBank accession numbers for rat DAF GPI and secreted forms are AF039583 and AF039584.

 
The full length coding region for both the GPI and secreted forms of rat DAF is shown in Fig. 1Go. A comparison of the amino acid sequence for the four SCRs and the ST-rich region with that in other species is shown in Fig. 2Go. Across this region, rat DAF is 67% identical to both forms of mouse DAF, 45% identical to guinea pig DAF, and 40% identical to human DAF, with all Cys residues conserved between species. Rat DAF has three potential N-glycosylation sites, one of which is identical to the single human N-glycosylation site at Asn61.



View larger version (56K):
[in this window]
[in a new window]
 
FIGURE 2. Alignment of amino acid sequences for SCR1–4 and ST-rich regions of the GPI forms of rat (RAT), mouse (MUR), guinea pig (GP), and human (HUM) DAF.

 
Detection of rat DAF expression in tissues

Northern blot analysis of mRNA from five tissues revealed a 2.4-kb species that was expressed abundantly in the lung and, on longer exposure, was also seen in the kidney, liver, and spleen (Fig. 3Go). A 1.4-kb species was expressed abundantly in the testes and, on longer exposure, was also detected in the lung, kidney, and spleen. Comparison of the expression level of each species in each tissue with the expression of GAPDH confirmed the predominance of the 2.4-kb species in lung and the extremely high level of expression of the 1.4-kb species in testis. Expression in other tissues was low or undetectable by this technique.



View larger version (51K):
[in this window]
[in a new window]
 
FIGURE 3. Northern blot analysis showing the relative expression of rat DAF transcripts in different tissues (testis (T), lung (Lu), liver (Li), kidney (K), spleen (S)) detected using a radiolabeled cDNA probe derived from the four SCRs. A GAPDH probe was used as a control for comparison of loading of mRNA between lanes; the densitometry values for each of the two major species (1.4- and 2.4-kb transcripts, arrowed) normalized for GAPDH expression are shown below the panel.

 
To ascertain whether rat DAF mRNA was expressed in these other tissues, we utilized RT-PCR analysis with primers specific for the two species. In each of the eight tissues studied, products specific for the GPI form of rat DAF were generated (Fig. 4GoA). Products specific for the secreted form of rat DAF were detected in all tissues except liver; expression was again most abundant in lung and testis and very low in brain (Fig. 4GoB). RT-PCR using GAPDH-specific primers generated specific bands of similar intensity in all tissues (Fig. 4GoC). All controls for nonspecific amplification were negative.



View larger version (72K):
[in this window]
[in a new window]
 
FIGURE 4. Southern blot analysis of PCR products showing relative expression of the GPI-linked (A) and secreted (B) forms of rat DAF in various tissues (testis (T), lung (Lu), liver (Li), kidney (K), spleen (S), small intestine (I), muscle (M), and brain (B)). Equal volumes of all PCR products were loaded, with the exception of the GPI-specific PCR of lung and testes, in which only one-quarter of the amount was applied to prevent overloading. C, GAPDH-specific primers were used to provide a comparison of levels of cDNA in the PCR reactions.

 
Rat DAF is encoded by a single gene

Genomic DNA was digested with restriction enzymes, Southern blotted, and probed with radiolabeled DNA specific for SCR1 and SCR3 (Fig. 5Go). BamHI and EcoRV digests gave single bands of 9.7 kb and 6.4 kb, respectively, with both SCR1- and SCR3-specific probes. The PstI digest produced single bands of 8.0 kb with SCR3 and 1.6 kb with SCR1. The XbaI digest produced a single band of 6.8 kb with SCR1, but two bands of 6.8 kb and 11 kb with SCR3. These two bands were equal in intensity and were approximately one-half the intensity of the bands from the BamHI and PstI digests. Double digests using combinations of BamHI, PstI, and EcoRV produced single bands when probed with either SCR1 or -3, whereas double digests using XbaI always produced two bands of reduced intensity (not shown).



View larger version (89K):
[in this window]
[in a new window]
 
FIGURE 5. Southern blot analysis of genomic DNA digested with BamHI (B), XbaI (X), PstI (P), and EcoRV (E). Blots were probed with radiolabeled probes specific for either SCR1 (A) or SCR3 (B).

 
Analysis of rat DAF gene cloned from genomic library

Screening of a rat genomic {lambda} phage library (4.8 x 105 pfu) with a mixture of SCR-specific cDNA probes identified four positive clones from separate plates. Digestion of purified phage DNA with NotI released inserts ranging from 12–19 kb, all of which were cloned into pBluescript. PCR within exons revealed that two clones contained all four SCRs, one clone contained only SCR1 and -2, while the fourth clone contained only SCR3 and -4. The data revealed that SCR3 was split between two exons 1.3 kb apart, hereafter termed SCR3a and SCR3b. PCR between exons determined that the size of intronic DNA between SCR1 and -2 was 2.5 kb, SCR2 and -3a was 1.6 kb, and SCR3b and -4 was 6 kb.

A genomic clone containing all four SCRs was digested with pstI and BamHI and cloned into pBluescript for sequencing. SCR1 and SCR2 were present in two separate 1.6-kb fragments from the pstI digestion. A 0.8-kb fragment from the pstI and BamHI double digest contained the DNA encoding the elusive signal peptide.

Expression of the GPI-anchored and secretory forms of rat DAF in NIH-3T3 cells

Expression was assessed by flow cytometry and Western blot using specific mouse mAbs against rat DAF, RDIII-7, and RDII-24, generated in-house. Fig. 6GoA shows the relative surface expression levels of the two forms of rat DAF as compared with the vector control-transfected cells. The level of expression of GPI-anchored rat DAF in the transfected cell line, assessed by flow cytometry, was 14-fold that of endogenous DAF on rat erythrocytes and 30-fold that of the rat fibroblast cell line RAT-2 (data not included). The secretory form of rat DAF showed low levels of cell surface expression, ~10-fold less than that of the GPI-linked form. Fig. 6GoB shows the effects of the three treatments on the expression of rat or human DAF on the transfected cells. Acid wash increased the levels of anti-rat DAF binding to the secretory DAF expressing cells by ~80%, but had little effect on binding to GPI-DAF-expressing cells; similarly, 1H4 binding to human DAF expressing cells was unaffected. Trypsinization also had little effect on human DAF expression, but almost completely removed both forms of rat DAF from the cell surface. PIPLC treatment reduced the levels of both human DAF and rat GPI-DAF by 90%, but caused a 20% increase in Ab binding to the cells expressing the secretory form of rat DAF.



View larger version (40K):
[in this window]
[in a new window]
 
FIGURE 6. Expression and functional analysis of rat DAF. A, Surface expression of human DAF, rat GPI and secreted DAF, and rat CD59 on NIH-3T3 cells, as measured by flow cytometry, compared with vector-transfected cells. Cells were stained with anti-rat DAF (RDIII-7), anti-rat CD59 (6D1), or anti-human DAF (1H4). B, Effect of low pH wash (number 2) or preincubation of cells with PIPLC (0.4 U/ml; number 3) or trypsin/EDTA (number 4) before primary Ab binding. All values are expressed as a percentage of mean cell fluorescence of untreated cells (number 1) and are means of triplicates ± SD. C, Comparison of C3 deposition on transfected cells after incubation in rat serum. C3 deposition was measured by flow cytometry using a monoclonal anti-C3 Ab and is expressed in mean cell fluorescence (MCF) units. All results are means of triplicates ± SD. Significant differences in C3 deposition compared with vector controls are indicated above the relevant columns.

 
Western blot of the cell medium under nonreducing conditions (Fig. 7GoA) identified two bands of 70 and 140 kDa, a very high molecular mass band from secretory rat DAF-transfected cells, and a single sharp 74-kDa band with rat GPI-DAF. Under reducing conditions (Fig. 7GoB), only the 70-kDa band was detected with the secretory form of rat DAF, and faint bands of 74 and 70 kDa were seen with the GPI forms of rat and human DAF, respectively. Western blot analysis of cell lysates under nonreducing conditions (Fig. 7GoC) revealed a band of 62 kDa for rat GPI-DAF, 70 kDa for human DAF, and 74 kDa for rat erythrocyte DAF, whereas no band could be detected with cells expressing the secretory form of rat DAF. No specific bands were observed in the vector control lanes, and blots using isotype control Ab were negative.



View larger version (66K):
[in this window]
[in a new window]
 
FIGURE 7. Western blots of rat DAF in supernatants and extracts of expressing cells. A, Cell supernatants from expressing cells run under nonreducing conditions and blotted with RDII-24 anti-rat DAF (vector control (Vec), rat GPI-DAF (GPI), rat secretory DAF (s)) or 1H4 anti-human DAF (human DAF (Hu)). B, Cell supernatants from expressing cells run under reducing conditions and blotted as described in A. C, Membrane lysates from expressing cells and rat erythrocytes enriched for GPI-anchored proteins by Triton X-114 partition run under nonreducing conditions and blotted as described in A above. Molecular weight markers are shown on the left of each panel. Control blots with isotype-matched irrelevant Abs showed no binding.

 
Function of the two forms of rat DAF on NIH-3T3 cells

Protection against C was assessed in transfected cells by measuring C3 deposition. Rat C3 deposition on each of the rat DAF-transfected lines, measured by flow cytometry, was compared with human DAF-transfected cells, using cells transfected with vector alone as a control. Cells highly expressing rat CD59 were also used as a control to determine whether any of the observed effects were artifacts of the high expression of protein at the cell surface. Vector control or rat CD59-expressing cells had similar, high levels of C3 deposited on their cell surface, whereas C3 deposition on human DAF- and rat GPI-DAF-expressing cells was reduced by ~70% (Fig. 6GoC). The cells expressing secretory rat DAF had a reduction in C3 deposition of ~20% compared with the controls.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
An understanding of C regulation in the rat, together with reagents enabling the principal CRP to be neutralized in vivo, will be of benefit in analyzing the contribution of C to homeostasis and disease. Characterization of rat CD59 and Crry has already provided some of these reagents, and neutralization of these CRP in vivo in rats has provided an abundance of new information (24, 25, 26, 27, 28). We have undertaken, therefore, to identify and characterize other CRP in the rat to increase our ability to interfere in vivo with C regulation in this species. We report here the cloning and characterization of the rat analogue of human DAF.

Within the last 2 years, the cloning of the cDNAs for both murine and guinea pig DAF have been described. Multiple cDNAs encoding guinea pig DAF were isolated from a spleen library (13). All encoded the four SCR structures that typify DAF and were identical with one another and 58% identical to human DAF through this region. However, alternative splicing generated several different isoforms that differed in the length of the ST-rich region, a feature also found in human MCP, in which the STP region is encoded on several exons that can be alternatively spliced (29). In addition, alternative splicing of two exons in the region encoding the carboxyl teminus of the protein-generated cDNAs encoding transmembrane, GPI-anchored, and secreted forms. Mouse DAF, independently cloned in three laboratories, provides an even more complex story (23, 30, 31). The protein was encoded on two separate genes, which were 85% identical at the nucleotide level and 78% identical at the amino acid level but encoded, respectively, GPI-anchored (Daf-gpi) and transmembrane (Daf-tm) forms of the protein. By Northern analysis, mRNA encoding the GPI-linked form of DAF was present in relative abundance in all tissues, whereas mRNA encoding the transmembrane form was abundant only in the testis and was weakly detected in lymphoid tissue. Mouse DAF GPI was 47% identical to both human and guinea pig DAF at the amino acid level (30).

Crry remains the only membrane CRP acting on the C3 convertase identified in the rat. The demonstration of DAF analogues in mice and guinea pigs led us to suspect that rats would also express DAF. We used a cDNA probe derived from the coding region of mouse DAF to screen a rat kidney cDNA library and identified clones containing the bulk of the rat DAF coding sequence (part of SCR2, the whole of SCR3 and -4, and the ST-rich region) that was highly homologous with the published sequence of mouse DAF, a long tail of 733 bp unrelated to published DAF sequences, and a 3'UTR region. The long tail encoded 112 amino acids of protein sequence before the stop codon, which contained no motifs predictive of GPI or transmembrane anchoring, suggesting that the product was secreted. This species was thus termed secreted DAF. Searches of protein and DNA databases have failed to identify any significant homologies with the tail, which represents a novel sequence. The same sequence was obtained from multiple clones and could be identified in mRNA isolated from rat tissues, making it unlikely that it was an artifact generated during creation of the cDNA library.

Most of the missing 5' sequence was obtained by 5'RACE, which generated a single specific product from rat kidney RNA containing the remainder of the cDNA coding for the mature protein, but only part of the signal peptide and no 5'UTR. All attempts to obtain the remainder of the signal peptide by modification of the 5'RACE reaction and use of a thermostable reverse transcriptase failed to produce a longer product. Isolation of phage containing portions of the rat DAF gene from the genomic library allowed cloning and sequencing of fragments of genomic DNA within which the signal peptide was identified. Analysis of this extra 5' sequence revealed a highly GC-rich region likely to form a hairpin loop in the RNA, perhaps explaining our inability to sequence this region by 5'RACE (Fig. 1Go).

A second form of rat DAF was obtained by 3'RACE using DNA from the kidney, lung, and testis. The product was, apart from an additional 51 bp encoding an extra 17 amino acids in the ST-rich region, identical to the library clone up to residue Gly347. Thereafter, the sequence encoded a hydrophobic stretch of 18 amino acids before a stop that was highly predictive of a GPI-addition consensus sequence, which was therefore termed GPI-DAF. The additional sequence, encoding residues Lys293 to Val309, was present in all 15 clones of GPI-DAF cDNA sequenced, but none of 5 secreted DAF cDNA clones. Mouse DAF is encoded on two closely linked genes, Daf-gpi and Daf-tm (23, 30, 31). Identity of sequence through the coding regions makes it highly likely that the two forms of rat DAF are encoded on a single gene and derived by alternative splicing. To confirm this possibility, we subjected genomic DNA to digestion with a panel of restriction enzymes chosen not to cut in the coding region and Southern blotted the digests with probes specific for SCR1 and SCR3 of rat DAF (Fig. 5Go). Both single and double digests of genomic DNA yielded only single bands when probed with either SCR1 or SCR3 for all four enzymes, with the sole exception of the XbaI digest probed with SCR3. In human DAF, SCR3 alone among the SCRs is encoded on two exons (32). In the rat, PCR across SCR3 in genomic phage clones produced a 1.5-kb product instead of the 192-bp product expected for a single exon, indicating that here too the SCR is encoded on two exons. The data thus clearly show that DAF is encoded on a single gene in the rat.

Northern blot analysis of purified mRNA probed with the the SCR region of rat DAF revealed two major bands of 2.4 and 1.4 kb, which were differentially expressed across a range of tissues (Fig. 3Go). These were similar in size to the two major bands of human DAF (2.2 and 1.5 kb), mouse GPI-DAF (2.8 and 1.4 kb), and guinea pig DAF (2.4–2.5 kb and 1.6–1.8 kb) (8, 13, 23). Expression of rat DAF mRNA was particularly abundant in the testis (1.4 kb predominant) and lung (2.4 kb predominant). RT-PCR of RNA from various tissues using primers specific for the GPI or secreted form of rat DAF identified both forms, expressed to varying degrees, in all tissues tested, with the exception of the liver, which did not express the secreted form (Fig. 4Go). By Northern blot analysis, only the 2.4-kb species was detectable in liver; we therefore suggest that the 2.4-kb species encodes GPI-DAF. The 1.4-kb species, extremely highly expressed in testis, is too small to encode secreted DAF, and therefore is likely also to encode the GPI form. This suggestion is supported by the RT-PCR data, which show that both testis (1.4 kb predominant) and lung (2.4 kb predominant) express an abundance of GPI-DAF. The reasons for this tissue specificity of length of mRNA species is unclear, but a similar situation pertains in the mouse, where the testis expresses only the smaller 1.4-kb transcript of GPI-DAF; this transcript is preferentially up-regulated by estrogen in the uterus (31), indicating that hormonal factors may play a part in regulating the expression of the two major RNA species.

To express the two full length rat DAF proteins in the absence of the signal peptide sequence, chimeras were constructed containing the signal peptide from mouse DAF. High level surface expression of GPI-DAF was achieved, as shown by flow cytometry and Western blot analysis of cell lysates. The protein was efficiently removed by PIPLC treatment, confirming GPI anchoring; unlike human DAF, it was trypsin sensitive (Fig. 6Go). A small amount of protein was present in the cell supernatants (Fig. 7Go). The expressed protein efficiently protected cells against C attack, reducing C3 fragment deposition by 70%; human CD59 was similarly effective in the same system, but rat CD59 expressed at high levels had no effect on C3 deposition (Fig. 6Go). Secreted DAF was abundant in the medium, as detected by Western blot (Fig. 7Go). Under nonreducing conditions, secreted DAF aggregated to form a high molecular mass aggregate, although some was present as a dimer (140 kDa) or monomer (70 kDa). Under reducing conditions, all of the aggregated protein reduced to the 70 kDa monomeric form. Flow cytometry revealed that a small proportion of secretory DAF was expressed on the cell surface (Fig. 6Go). The mechanism by which this protein attaches to the membrane is not clear, but treatment with PIPLC failed to remove the protein, and acid washing to disrupt noncovalent interactions similarly had no effect. Cell-bound secreted DAF did confer some protection against C attack, reducing C3 fragment deposition by ~25% compared with controls.

The data demonstrate that rats, like mice, express in addition to Crry an analogue of human DAF. No information has yet been published on the expression of mouse DAF protein, and no function has been demonstrated. Here, we show that rat DAF protein is an inhibitor of C and is abundantly expressed on rat erythrocytes and rat cell lines. It will be of interest to analyze the relative contributions of Crry and DAF to the protection of rat cells in vitro and in vivo.


    Footnotes
 
1 This work was funded by the Wellcome Trust. B.P.M. is a Wellcome Trust Senior Clinical Research Fellow. S.J.H. is the holder of a Wellcome Prize Studentship. Back

2 The nucleotide sequences used in this study are registered under GenBank accession numbers AF039583 and AF039584. Back

3 Address correspondence and reprint requests to Dr. B. Paul Morgan, Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff, CF4 4XX, U.K. E-mail address: Back

4 Abbreviations used in this paper: CRP, complement regulatory protein; DAF, decay-accelerating factor; RDAF, rat DAF-specific primer; RACE, rapid amplification of cDNA ends; UTR, untranslated region; GPI, glycosylphosphatidylinositol; PIPLC, phosphatidylinositol-specific phospholipase C; MCP, membrane cofactor protein; RCA, regulators of C activation; SCR, short consensus repeat; pfu, plaque-forming unit; GAPDH, glyceraldehyde phosphate dehydrogenase. Back

Received for publication January 29, 1998. Accepted for publication July 20, 1998.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Morgan, B. P., S. Meri. 1994. Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15:369.[Medline]
  2. Rey-Campos, J., P. Rubinstein, S. Rodriguez de Cordoba. 1988. A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP. J. Exp. Med. 167:664.[Abstract/Free Full Text]
  3. Carroll, M. C., E. M. Alicot, P. J. Katzman, L. B. Klickstein, J. A. Smith, D. T. Fearon. 1988. Organization of the genes encoding complement receptors type 1 and 2, decay-accelerating factor, and C4-binding protein in the RCA locus on human chromosome 1. J. Exp. Med. 167:1271.[Abstract/Free Full Text]
  4. Lublin, D. M., J. P. Atkinson. 1989. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7:35.[Medline]
  5. Nakano, Y., K. Sumida, N. Kikuta, N. H. Miura, T. Tobe, M. Tomita. 1992. Complete determination of disulfide bonds localized within the short consensus repeat units of decay accelerating factor (CD55 antigen). Biochim. Biophys. Acta 1116:235.[Medline]
  6. Coyne, K. E., S. E. Hall, S. Thompson, M. A. Arce, T. Kinoshita, T. Fujita, D. J. Anstee, W. Rosse, D. M. Lublin. 1992. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J. Immunol. 149:2906.[Abstract]
  7. Brodbeck, W. G., D. Liu, J. Sperry, C. Mold, M. E. Medof. 1996. Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor. J. Immunol. 156:2528.[Abstract]
  8. Caras, I. W., M. A. Davitz, L. Rhee, G. Weddell, Jr D. W. Martin, V. Nussenzweig. 1987. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature 325:545.[Medline]
  9. Nicholson-Weller, A., J. Burge, K. F. Austen. 1981. Purification from guinea pig erythrocyte stroma of a decay-accelerating factor for the classical c3 convertase, C4b,2a. J. Immunol. 127:2035.[Abstract]
  10. Sugita, Y., M. Uzawa, M. Tomita. 1987. Isolation of decay-accelerating factor (DAF) from rabbit erythrocyte membranes. J. Immunol. Methods 104:123.[Medline]
  11. Kameyoshi, Y., M. Matsushita, H. Okada. 1989. Murine membrane inhibitor of complement which accelerates decay of human C3 convertase. Immunology 68:439.[Medline]
  12. Nickells, M. W., J. P. Atkinson. 1990. Characterization of CR1- and membrane cofactor protein-like proteins of two primates. J. Immunol. 144:4262.[Abstract]
  13. Nonaka, M., T. Miwa, N. Okada, M. Nonaka, H. Okada. 1995. Multiple isoforms of guinea pig decay-accelerating factor (DAF) generated by alternative splicing. J. Immunol. 155:3037.[Abstract]
  14. Takizawa, H., N. Okada, H. Okada. 1994. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J. Immunol. 152:3032.[Abstract]
  15. Quigg, R. J., C. F. Lo, J. J. Alexander, III A. E. Sneed, G. Moxley. 1995. Molecular characterization of rat Crry: widespread distribution of two alternative forms of Crry mRNA. Immunogenetics 42:362.[Medline]
  16. Charreau, B., A. Cassard, L. Tesson, B. Le Mauff, J. M. Navenot, D. Blanchard, D. Lublin, J. P. Soulillou, I. Anegon. 1994. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation 58:1222.[Medline]
  17. Hughes, T. R., S. J. Piddlesden, J. D. Williams, R. A. Harrison, B. P. Morgan. 1992. Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem. J. 284:169.
  18. Frohman, M. A.. 1990. Rapid amplification of complementary DNA ends for generation of full-length complementary DNAs: thermal RACE. PCR Protocols: A Guide to Methods and Applications 28. Academic Press, London.
  19. Laird, P. W., Z. A., L. K., M. A. Rudnicki, J. R., and B. A. 1991. Simplified mammalian DNA isolation procedure. Nucleic Acids. Res. 19:4293.
  20. Rushmere, N. K., S. Tomlinson, B. P. Morgan. 1997. Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function. Immunology 90:640.[Medline]
  21. Powell, M. B., K. J. Marchbank, N. K. Rushmere, C. W. van den Berg, B. P. Morgan. 1997. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J. Immunol. 158:1692.[Abstract]
  22. Spiller, O. B., S. M. Hanna, D. V. Devine, F. Tufaro. 1997. Neutralization of cytomegalovirus virions: the role of complement. J. Infect. Dis. 176:339.[Medline]
  23. Spicer, A. P., M. F. Seldin, S. J. Gendler. 1995. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes: duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J. Immunol. 155:3079.[Abstract]
  24. Matsuo, S., S. Ichida, H. Takizawa, N. Okada, L. Baranyi, A. Iguchi, B. P. Morgan, H. Okada. 1994. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J. Exp. Med. 180:1619.[Abstract/Free Full Text]
  25. Ichida, S., Y. Yuzawa, H. Okada, K. Yoshioka, S. Matsuo. 1994. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int. 46:89.[Medline]
  26. Nomura, A., K. Nishikawa, Y. Yuzawa, H. Okada, N. Okada, B. P. Morgan, S. J. Piddlesden, M. Nadai, T. Hasegawa, S. Matsuo. 1995. Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J. Clin. Invest. 96:2348.
  27. Nishikawa, K., S. Matsuo, N. Okada, B. P. Morgan, H. Okada. 1996. Local inflammation caused by a monoclonal antibody that blocks the function of the rat membrane inhibitor of C3 convertase. J. Immunol. 156:1182.[Abstract]
  28. Mizuno, M., K. Nishikawa, R. M. Goodfellow, S. J. Piddlesden, B. P. Morgan, S. Matsuo. 1997. The effects of functional suppression of a membrane-bound complement regulatory protein, CD59, in the synovial tissue in rats. Arthritis Rheum. 40:527.[Medline]
  29. Russell, S. M., R. L. Sparrow, I. F. McKenzie, D. F. Purcell. 1992. Tissue-specific and allelic expression of the complement regulator CD46 is controlled by alternative splicing. Eur. J. Immunol. 22:1513.[Medline]
  30. Fukuoka, Y., A. Yasui, N. Okada, H. Okada. 1996. Molecular cloning of murine decay accelerating factor by immunoscreening. Int. Immunol. 8:379.[Abstract/Free Full Text]
  31. Song, W. C., C. Deng, K. Raszmann, R. Moore, R. Newbold, J. A. McLachlan, M. Negishi. 1996. Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J. Immunol. 157:4166.[Abstract]
  32. Post, T. W., M. A. Arce, M. K. Liszewski, E. S. Thompson, J. P. Atkinson, D. M. Lublin. 1990. Structure of the gene for human complement protein decay accelerating factor. J. Immunol. 144:740.[Abstract]



This article has been cited by other articles:


Home page
Mult SclerHome page
R P Lisak, J A Benjamins, B Bealmear, B Yao, S Land, L Nedelkoska, and D Skundric
Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures
Multiple Sclerosis, April 1, 2006; 12(2): 149 - 168.
[Abstract] [PDF]


Home page
J EndocrinolHome page
M. C Gieske, G. Y. Na, Y. Koo, M. Jo, T. E Curry Jr, and C. Ko
Decay-accelerating factor in the periovulatory rat ovary
J. Endocrinol., August 1, 2005; 186(2): 303 - 313.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Andoh, K. Kinoshita, I. Rosenberg, and D. K. Podolsky
Intestinal Trefoil Factor Induces Decay-Accelerating Factor Expression and Enhances the Protective Activities Against Complement Activation in Intestinal Epithelial Cells
J. Immunol., October 1, 2001; 167(7): 3887 - 3893.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y.-M. Qian, X. Qin, T. Miwa, X. Sun, J. A. Halperin, and W.-C. Song
Identification and Functional Characterization of a New Gene Encoding the Mouse Terminal Complement Inhibitor CD59
J. Immunol., September 1, 2000; 165(5): 2528 - 2534.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Perez de la Lastra, C. L. Harris, S. J. Hinchliffe, D. S. Holt, N. K. Rushmere, and B. P. Morgan
Pigs Express Multiple Forms of Decay-Accelerating Factor (CD55), All of Which Contain Only Three Short Consensus Repeats
J. Immunol., September 1, 2000; 165(5): 2563 - 2573.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. McGrath, G. W. G. Wilkinson, O. B. Spiller, and B. P. Morgan
Development of Adenovirus Vectors Encoding Rat Complement Regulators for Use in Therapy in Rodent Models of Inflammatory Diseases
J. Immunol., December 15, 1999; 163(12): 6834 - 6840.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. J. Alexander, B. K. Hack, P. N. Cunningham, and R. J. Quigg
A Protein with Characteristics of Factor H Is Present on Rodent Platelets and Functions as the Immune Adherence Receptor
J. Biol. Chem., August 17, 2001; 276(34): 32129 - 32135.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hinchliffe, S. J.
Right arrow Articles by Morgan, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hinchliffe, S. J.
Right arrow Articles by Morgan, B. P.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS